OrbiMed, BDC, NEA backed Clementia Pharmaceuticals files for IPO on NASDAQ

Photo of author

By Ted Liu

Clementia Pharmaceuticals Inc. has filed a form F-1 for a proposed initial public offering (IPO) of its common shares.

Clementia Pharmaceuticals has applied to list its share on The Nasdaq Global Market under the symbol “CMTA”.

The underwriting syndicate is led by Morgan Stanley and Leerink Partners and includes Wedbush PacGrow and BTIG. Jenner & Block LLP and Ropes & Gray LLP act as legal counsels to Clementia and underwriters respectively.

Founded in 2010, Clementia Pharmaceuticals Inc. has raised US $102.8 million in three rounds of financing from OrbiMed Advisors, LLC, BDC Capital, New Enterprise Associates (NEA), Janus Global Life Sciences Fund, RA Capital Healthcare Fund, L.P., UCB BioPharma, Rock Springs Capital Master Fund LP, EcoR1 Capital, Leerink Holdings LLC, Fonds des solidarité FTQ, and private investors.

OrbiMed, BDC Capital and NEA collectively control 73.7% of pre-IPO shares.

Clementia Pharmaceuticals is led by Dr. Clarissa Desjardins, founder & CEO, Dr. Donna Grogan, Chief Medical Officer, Jeff Packman, Chief Development Officer, Eric Grinstead, Chief Commercial Officer, and Michael Singer, Chief Financial Officer.

Clementia Pharmaceuticals is a clinical stage biopharmaceutical company that is developing disease-modifying treatments for patients suffering from debilitating bone and other diseases with high unmet medical need. The company is developing its first lead product candidate, palovarotene, to treat fibrodysplasia ossificans progressiva (FOP), an ultra-rare and severely disabling disorder, and other diseases.

Clementia Pharmaceuticals is headquartered in Montreal with a U.S. subsidiary in Boston.